Mpm Bioimpact LLC
Mpm Bioimpact LLC reported 37 holdings worth US$1.64B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Mpm Bioimpact LLC reported 37 holdings worth US$1.64B as of Jun 30, 2026. Largest: Cullinan Therapeutics, Inc., Aktis Oncology, Inc. and Liquidia Corporation. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 37
- Value as reported
- US$1.64B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cullinan Therapeutics, Inc. | 9.73M | US$177M | 10.8% |
| Aktis Oncology, Inc. | 4.84M | US$156M | 9.5% |
| Liquidia Corporation | 1.39M | US$111M | 6.7% |
| Revolution Medicines, Inc. | 492K | US$92.2M | 5.6% |
| Corcept Therapeutics Incorporated | 771K | US$67M | 4.1% |
| Edgewise Therapeutics, Inc. | 1.62M | US$65.9M | 4.0% |
| Travere Therapeutics, Inc. | 1.12M | US$63.8M | 3.9% |
| Dbv Technologies Sa | 3.67M | US$60.1M | 3.7% |
| Trevi Therapeutics, Inc. | 3.07M | US$57.3M | 3.5% |
| Alumis Inc. | 2.02M | US$56.8M | 3.5% |
| Ultragenyx Pharmaceutical Inc. | 1.42M | US$47.4M | 2.9% |
| Relay Therapeutics, Inc. | 2.42M | US$45.2M | 2.8% |
| Abivax Sa | 336K | US$44.8M | 2.7% |
| Dyne Therapeutics, Inc. | 1.92M | US$42.7M | 2.6% |
| Dianthus Therapeutics, Inc. | 420K | US$40.9M | 2.5% |
| Bioage Labs, Inc. | 1.67M | US$40.9M | 2.5% |
| Palvella Therapeutics, Inc. | 204K | US$31.2M | 1.9% |
| Taysha Gene Therapies, Inc. | 4.5M | US$30.6M | 1.9% |
| Syndax Pharmaceuticals, Inc. | 1.33M | US$29.2M | 1.8% |
| Monte Rosa Therapeutics, Inc. | 1.16M | US$28.1M | 1.7% |
| Zura Bio Limited | 4.47M | US$26.4M | 1.6% |
| Natera, Inc. | 92,638 | US$25.1M | 1.5% |
| Stoke Therapeutics, Inc. | 723K | US$23.7M | 1.4% |
| Forte Biosciences, Inc. | 987K | US$21M | 1.3% |
| Oric Pharmaceuticals, Inc. | 1.88M | US$20.4M | 1.2% |
| Tarsus Pharmaceuticals, Inc. | 322K | US$20.3M | 1.2% |
| Annexon, Inc. | 3.54M | US$20.2M | 1.2% |
| Bright Minds Biosciences Inc. | 202K | US$14.2M | 0.87% |
| Entrada Therapeutics, Inc. | 1.25M | US$9.22M | 0.56% |
| Aclaris Therapeutics, Inc. | 1.04M | US$5.51M | 0.34% |
| Context Therapeutics Inc. | 1.3M | US$720K | 0.04% |
| Werewolf Therapeutics, Inc. | 80,142 | US$28,851 | <0.01% |
| Corvus Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Cytokinetics, Incorporated | 0 | US$0 | 0.00% |
| Engene Holdings Inc. | 0 | US$0 | 0.00% |
| Evommune, Inc. | 0 | US$0 | 0.00% |
| Viridian Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Zymeworks Inc. | 0 | US$0 | 0.00% |
| Agios Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Allogene Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Arcutis Biotherapeutics, Inc. | 0 | US$0 | 0.00% |
| Climb Bio, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related